India-based Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines. The company enjoys a strong position in the generics market.
Currently, Dr. Reddy’s has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Rise: Dr. Reddy’s fourth quarter fiscal 2019 earnings of 38 cents per ADS, compared with 26 cents reported in the year ago quarter.
Revenues Beat: Dr. Reddy’s posted revenues of $581 million an increase of 13.7% year over year. The Zacks Consensus Estimates was pegged at $565.46 million.
Key Statistics: Revenues from Global Generics segment increased 9% year over year, and from the Pharmaceutical Services and Active Ingredients (PSAI) segment increased 8% year over year. Sales from the Proprietary Products segment surged 139% from the year ago quarter.
Full Year Result: The company reported a revenues of $2.2 billion, an increase of 8.3% year-over-year. The company’s earnings for the fiscal 2019 was $1.64 per ADS, up 92.9% compared to year-ago period.
Pre-Market Trading: Shares were up 0.2% in pre-market trading.
Check back later for our full write up on this RDY earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>